ICH Project 27th ICH Immediate Report

Nov 02, 2012

The 27th ICH Informal Meeting was held on December 14, 2012 at Yakult Hall in Tokyo to share the outcome of the ICH Regular Meeting held in San Diego, USA, from November 10 to 15, 2012, with companies in charge of drug development and safety assurance. The meeting was held on December 14, 2012 at Yakult Hall in Tokyo, Japan.

In addition to a general report on the latest developments in ICH, this debriefing session included reports and Q&A sessions by subject matter experts on trends in topics related to electronic standards for the communication of regulatory information, efficacy, safety, and quality of drugs. The program, timetable, and presentation materials for this symposium are attached below as files for direct viewing.
Unauthorized copying or reproduction of the attached materials is strictly prohibited.

Date, time and place

Date and Time Location
Friday, December 14, 2012, 10:00-16:00 Yakult Honsha Building, 1-1-19 Higashi-Shinbashi, Minato-ku, Tokyo

Information and Program

Meeting Information/Program (298KB)

Presentation materials

  Presentation Speaker

 

00_Opening Remarks (282KB)

Hironobu Saito (Daiichi Sankyo)

 

01_Latest Trends of ICH (201KB)

Yasuko Inokuma (Ministry of Health, Labour and Welfare)

Trends in Topics on Electronic Standards for Communication of Drug Regulatory Information

02_E2B (R3) Data Items for Transmitting Individual Case Safety Report (549KB)

Ayumi Endo (NIH)

03_M5: Data Items and Criteria for Drug Dictionary (917KB)

Toru KIMURA (GlaxoSmithKline)

Trends in Efficacy Topics

04_E2C (R2): PBRER Step 4 Guideline (617KB)

Yoko Hattori (Daiichi Sankyo)

Trends in Safety Topics

05_S1:Carcinogenicity Studies (Review) (2,292KB)

Akiyoshi Nishikawa (National Institute of Health Sciences)

06_S10:Photo safety study (546KB)

Kazuhiro HOSOI (Santen Pharmaceutical)

07_M7: Evaluation and Control of DNA Reactive (Mutagenic) Impurities in Drugs to Reduce Potential Carcinogenic Risk (698KB)

Masamitsu HONMA (National Institute of Public Health)

Trends in Quality Topics

08_Q3D: Metal Impurities After the San Diego Meeting (397KB)

Chikako SHIKATA (NIHS)

09_Q7: API GMP Q&A (1,382KB)

Tetsuhito Takarada(Mochida Pharmaceutical Co.)

The End

Share this page

TOP